Albemarle Q3 net sales rise 19% to $1.6 billion; Specialties outlook raised
Albemarle reported third-quarter 2026 net sales of $1.6 billion, up 19% from a year earlier, and net income attributable to the company of $297 million, or $2.15 per diluted share, compared with a loss of $1.72 per share in the prior-year quarter. The company raised its full-year 2026 Specialties adjusted EBITDA outlook to $350-$375 million and cut its capital expenditure forecast to $300-$350 million, but said fourth-quarter net sales and adjusted EBITDA are expected to decline sequentially on lower lithium market pricing.
Key points
- Q3 2026 net sales were $1,553.1 million, up 18.8% from $1,307.8 million in Q3 2025; adjusted EBITDA was $645.5 million, up 186.1%.
- Diluted EPS was $2.15; adjusted diluted EPS was $2.58, compared with an adjusted loss of $0.19 in Q3 2025.
- Full-year 2026 Specialties adjusted EBITDA outlook was raised to $350-$375 million from $275-$325 million.
- Full-year 2026 capital expenditure forecast was reduced to $300-$350 million from approximately $500 million; Q4 2026 net sales and adjusted EBITDA are expected to decrease sequentially.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.